Acceptability of unsupervised peer-based distribution of HIV oral self-testing for the hard-to-reach in rural KwaZulu Natal, South Africa: Results from a demonstration study.
Journal
PloS one
ISSN: 1932-6203
Titre abrégé: PLoS One
Pays: United States
ID NLM: 101285081
Informations de publication
Date de publication:
2022
2022
Historique:
received:
14
06
2021
accepted:
10
02
2022
entrez:
30
3
2022
pubmed:
31
3
2022
medline:
15
4
2022
Statut:
epublish
Résumé
Innovative models to distribute oral HIV self-tests (HIVST) provide an opportunity to increase access to HIV testing, especially for hard-to-reach populations. This study aimed to describe the acceptability of unsupervised peer-distribution of HIVST as a method to scale-up HIV testing. In this study, lay counsellors or community health workers provided HIVST kits to primary recipients (PRs) for distribution to their sexual partners, anyone in their social network (termed secondary recipients) or for self-testing, from September 2018 to March 2020. The study was conducted in Eshowe and Mbongolwane areas in KwaZulu-Natal, South Africa. A structured questionnaire was administered during the recruitment and passive follow-up, when people came for confirmatory HIV testing. Electronic records were retrospectively examined to determine initiation of antiretroviral treatment (ART) for all HIVST users and non-users. Among 36,708 people approached to be primary recipients, 9,891 (26.9%) accepted; 31,341 HIVST kits were distributed with a median of three (IQR: 2-4) per peer. PRs were predominately recruited at primary health clinics (PHCs). However, acceptability of HIVST was thrice as high at community-based testing sites compared to PHCs (64.5% vs. 21.0%; p<0.001). During the study period, 34,715 adults were tested for HIV at both PHCs and community-based testing sites; of these, 1,089 individuals reported HIVST use. Among HIVST users, 893 (82.0%) returned to the clinic for confirmatory testing after testing negative on HIVST; 196 (17.9%) were confirmed HIV positive following a positive HIVST. After excluding 36/196 (18.4%) participants for whom clinical records could not be found in electronic register and 25/160 (15.6%) who were already on ART before receiving HIVST, 129/135 (95.5%) initiated ART, whereas 2,362/2685 (88%) of HIV positive HIVST non-users-initiated ART. Unsupervised peer-distribution of HIVST was feasible and acceptable, with more than 25% accepting to be peer-distributors. Acceptability of HIVST was thrice as high in community sites compared to clinics.
Sections du résumé
BACKGROUND
Innovative models to distribute oral HIV self-tests (HIVST) provide an opportunity to increase access to HIV testing, especially for hard-to-reach populations. This study aimed to describe the acceptability of unsupervised peer-distribution of HIVST as a method to scale-up HIV testing.
METHODS
In this study, lay counsellors or community health workers provided HIVST kits to primary recipients (PRs) for distribution to their sexual partners, anyone in their social network (termed secondary recipients) or for self-testing, from September 2018 to March 2020. The study was conducted in Eshowe and Mbongolwane areas in KwaZulu-Natal, South Africa. A structured questionnaire was administered during the recruitment and passive follow-up, when people came for confirmatory HIV testing. Electronic records were retrospectively examined to determine initiation of antiretroviral treatment (ART) for all HIVST users and non-users.
RESULTS
Among 36,708 people approached to be primary recipients, 9,891 (26.9%) accepted; 31,341 HIVST kits were distributed with a median of three (IQR: 2-4) per peer. PRs were predominately recruited at primary health clinics (PHCs). However, acceptability of HIVST was thrice as high at community-based testing sites compared to PHCs (64.5% vs. 21.0%; p<0.001). During the study period, 34,715 adults were tested for HIV at both PHCs and community-based testing sites; of these, 1,089 individuals reported HIVST use. Among HIVST users, 893 (82.0%) returned to the clinic for confirmatory testing after testing negative on HIVST; 196 (17.9%) were confirmed HIV positive following a positive HIVST. After excluding 36/196 (18.4%) participants for whom clinical records could not be found in electronic register and 25/160 (15.6%) who were already on ART before receiving HIVST, 129/135 (95.5%) initiated ART, whereas 2,362/2685 (88%) of HIV positive HIVST non-users-initiated ART.
CONCLUSION
Unsupervised peer-distribution of HIVST was feasible and acceptable, with more than 25% accepting to be peer-distributors. Acceptability of HIVST was thrice as high in community sites compared to clinics.
Identifiants
pubmed: 35353823
doi: 10.1371/journal.pone.0264442
pii: PONE-D-21-19545
pmc: PMC8967037
doi:
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
e0264442Déclaration de conflit d'intérêts
The authors have declared that no competing interests exist.
Références
BMC Public Health. 2019 Oct 15;19(1):1289
pubmed: 31615461
BMC Infect Dis. 2019 Sep 18;19(1):814
pubmed: 31533646
BMC Public Health. 2019 Jul 8;19(1):898
pubmed: 31286953
EClinicalMedicine. 2021 Jul 07;38:100991
pubmed: 34278282
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25238
pubmed: 30907491
PLoS One. 2019 Apr 15;14(4):e0215353
pubmed: 30986228
J Acquir Immune Defic Syndr. 2019 Aug 15;81(5):e160-e162
pubmed: 31021989
PLoS Med. 2015 Sep 08;12(9):e1001873
pubmed: 26348035
Trop Med Int Health. 2016 Jun;21(6):759-67
pubmed: 27098272
EClinicalMedicine. 2020 Apr 18;21:100327
pubmed: 32322811
J Int AIDS Soc. 2019 Mar;22 Suppl 1:e25244
pubmed: 30907505
J Int AIDS Soc. 2017 Jun 26;20(1):21610
pubmed: 28691442
PLoS One. 2020 Aug 7;15(8):e0236141
pubmed: 32764751
AIDS Behav. 2018 Feb;22(2):560-568
pubmed: 28699017
PLoS Med. 2016 Nov 8;13(11):e1002166
pubmed: 27824882
J Int AIDS Soc. 2017 Aug 29;20(Suppl 6):21751
pubmed: 28872275
J Int AIDS Soc. 2017 May 15;20(1):21594
pubmed: 28530049
Bull World Health Organ. 2019 Nov 1;97(11):764-776
pubmed: 31673192
Public Health. 2017 Feb;143:1-7
pubmed: 28159020
Lancet HIV. 2016 Jun;3(6):e266-74
pubmed: 27240789
PLoS Med. 2019 Jan 2;16(1):e1002719
pubmed: 30601823
PLoS One. 2018 Nov 29;13(11):e0208191
pubmed: 30496260